EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis

Omar Khasawneh, Kyrillos Mahrous Gerges, Islam Khasawneh, Edoardo V Savarino, Brigida Barberio, Ahmed Farid Gadelmawla, Basma Mansor Elhabbasi, Maram Albandak, Abdelmoneim Taher Mohamed, Hala Abubkr Shlibek, Bisher Sawaf, Miguel Regueiro und 1 weitere

Digestive Diseases · 18.08.2026 · 1-24

DOI: 10.1159/000553479 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Digestive Diseases, online erschienen am 18.08.2026. Verfasst von Omar Khasawneh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to investigate the effects of GLP-1 receptor agonists (GLP-1 RAs) on weight, metabolic, and inflammatory bowel disease (IBD) activity parameters in patients with IBD.

Methods

We conducted a systematic search for studies using GLP-1 RAs in IBD patients. The primary outcomes included weight (body mass index, total body weight, total weight loss percentage [TWL%], and >5 and >10 weight loss [WL]) and metabolic parameters (lipid panel and glycated hemoglobin [HbA1c]), while IBD-activity parameters and adverse events were secondary outcomes.

Results

Ten studies were included (n = 7,831). Weight parameters showed reductions, with a TWL% of −7.55% (95% confidence interval [CI]: −3.99 to −11.12), with 60% achieving WL >5% (95% CI: 53 to 67) and 40% achieving WL >10% (95% CI: 33 to 47). Metabolic parameters showed improved and stabilized levels, of which LDL decreased from 94.96 mg/dL (95% CI: 79.91 to 110.00) to 90.45 mg/dL (95% CI: 81.58 to 99.33), and HbA1c, in diabetics, from 7.11% (95% CI: 6.62 to 7.59) to 6.76% (95% CI: 6.35 to 7.16). GLP-1 RAs seem not to exacerbate IBD activity, with improved fecal calprotectin from 289.46 μg/g (95% CI: 62.88 to 516.04) to 210.59 μg/g (95% CI: 75.45 to 345.73), with 11% and 6% requiring IV steroids and advanced therapy, respectively. Adverse events occurred at lower rates, with nausea/vomiting being the most common.

Conclusion

Our findings suggest that GLP-1 RAs may be promising for reducing weight and improving metabolic parameters without exacerbating activity, and may be a safe option for IBD patients. However, larger randomized controlled trials are needed to assess causal inference and long-term effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesGlucagon-Like Peptide-1 Receptor AgonistsHumansGlycated HemoglobinBody Weight

Stichwörter der Autor:innen

GLP-1 receptor agonistsInflammatory bowel diseaseMeta-analysisSystematic review

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobin

Autor:innen und Institutionen

  • Department of Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
  • Faculty of Medicine, Sohag University, Sohag, Egypt.
  • Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda-Ospedale Università di Padova, University of Padova, Padova, Italy.
  • Faculty of Medicine, Menoufia University, Menoufia, Egypt.
  • Faculty of Dentistry, University of Tripoli, Tripoli, Libya.
  • Department of Internal Medicine, University of Toledo, Toledo, Ohio, USA.

Zitieren

APA

Khasawneh, O., Gerges, K. M., Khasawneh, I., Savarino, E. V., Barberio, B., Gadelmawla, A. F., Elhabbasi, B. M., Albandak, M., Mohamed, A. T., Shlibek, H. A., Sawaf, B., Regueiro, M., & Elhadi, M. (2026). Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis. Digestive Diseases, 1-24. https://doi.org/10.1159/000553479

Vancouver

Khasawneh O, Gerges KM, Khasawneh I, Savarino EV, Barberio B, Gadelmawla AF, et al. Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis. Digestive Diseases. 2026:1-24. doi:10.1159/000553479

BibTeX
@article{Khasawneh2026,
  author = {Khasawneh, Omar and Gerges, Kyrillos Mahrous and Khasawneh, Islam and Savarino, Edoardo V and Barberio, Brigida and Gadelmawla, Ahmed Farid and Elhabbasi, Basma Mansor and Albandak, Maram and Mohamed, Abdelmoneim Taher and Shlibek, Hala Abubkr and Sawaf, Bisher and Regueiro, Miguel and Elhadi, Muhammed},
  title = {Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis},
  journal = {Digestive Diseases},
  year = {2026},
  pages = {1--24},
  doi = {10.1159/000553479}
}
Kostenlos starten →